RT Journal Article SR Electronic T1 Population based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high grade serous ovarian cancer JF medRxiv FD Cold Spring Harbor Laboratory Press SP 19011924 DO 10.1101/19011924 A1 Honglin Song A1 Ed Dicks A1 Jonathan P. Tyrer A1 Maria Intermaggio A1 Georgia Chenevix-Trench A1 David D Bowtell A1 Nadia Traficante A1 AOCS Group A1 James D. Brenton A1 Teodora Goranova A1 Karen Hosking A1 Anna Piskorz A1 Elke Van Oudenhove A1 Jennifer Anne Doherty A1 Holly R. Harris A1 Mary Anne Rossing A1 Matthias Dürst A1 Thilo Dörk A1 Natalia V. Bogdanova A1 Francesmary Modugno A1 Kirsten B. Moysich A1 Kunle Odunsi A1 Roberta B. Ness A1 Beth Y. Karlan A1 Jenny Lester A1 Allan Jensen A1 Susanne K. Kjaer A1 Estrid Høgdall A1 Ian Campbell A1 Conxi Lazaro A1 Miquel Angel Pujana A1 Julie M. Cunningham A1 Robert A. Vierkant A1 Stacey J. Winham A1 Michelle A.T. Hildebrandt A1 Chad Huff A1 Donghui Li A1 Xifeng Wu A1 Yao Yu A1 Jennifer B. Permuth A1 Douglas A. Levine A1 Joellen M. Schildkraut A1 Marjorie J. Riggan A1 Andrew Berchuck A1 Penelope M. Webb A1 OPAL Study Group A1 Cezary Cybulski A1 Jacek Gronwald A1 Anna Jakubowska A1 Jan Lubiński A1 Jennifer Alsop A1 Patricia A. Harrington A1 Isaac Chan A1 Usha Menon A1 Celeste L. Pearce A1 Anna H. Wu A1 Anna de Fazio A1 Catherine J. Kennedy A1 Ellen L. Goode A1 Susan J. Ramus A1 Simon A. Gayther A1 Paul D.P. Pharoah YR 2019 UL http://medrxiv.org/content/early/2019/11/29/19011924.abstract AB Purpose The known EOC susceptibility genes account for less than 50% of the heritable risk of ovarian cancer suggesting other susceptibility genes exist. The aim of this study was to evaluate the contribution to ovarian cancer susceptibility of rare deleterious germline variants in a set of candidate genes.Methods We sequenced the coding region of 54 candidate genes in 6385 invasive EOC cases and 6115 controls of broad European ancestry. Genes with an increased frequency of putative deleterious variants in cases verses controls were further examined in an independent set of 14,146 EOC cases and 28,661 controls from the ovarian cancer association consortium and the UK Biobank. For each gene, we estimated the EOC risks and evaluated associations between germline variant status and clinical characteristics.Results The odds ratios (OR) associated for high-grade serous ovarian cancer were 3.01 for PALB2 (95% CI 1.59 – 5.68; P = 0.00068), 1.99 for POLK (95% CI 1.15 – 3.43; P = 0.014), and 4.07 for SLX4 (95% CI 1.34-12.4; P = 0.013). Deleterious mutations in FBXO10 were associated with a reduced risk of disease (OR 0.27, 95% CI 0.07 −1.00, P=0.049). However, based on the Bayes false discovery probability, only the association for PALB2 in high-grade serous ovarian cancer is likely to represent a true positive.Conclusions We have found strong evidence that carriers of PALB2 deleterious mutations are at increased risk of high-grade serous ovarian cancer. Whether the magnitude of risk is sufficiently high to warrant the inclusion of PALB2 in cancer gene panels for ovarian cancer risk testing is unclear; much larger sample sizes will be needed to provide sufficiently precise estimates for clinical counselling.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research has been supported by NIH/NCI grants R01CA178535 and R01CA188943. The University of Cambridge has received salary support in respect of PDPP from the NHS in the East of England through the Clinical Academic Reserve. SAG is a recipient of the Barth Family Chair in Cancer Genetics. Holly Harris (HRH) is supported by the National Cancer Institute, National Institutes of Health (K22 CA193860). Dr. Beth Karlan is funded by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National Center for Advancing Translational Sciences (NCATS), Grant UL1TR000124. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from authors on request